Cannot Predict Who Responds to Immunotherapies | Response is 60% or More If therapy is Given First Line

Cannot Predict Who Responds to Immunotherapies | Response is 60% or More If therapy is Given First Line

Annual-Meeting

1 year
160 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Paul Nghiem, MD, PhD, University of Washington, shares Cannot Predict Who Responds to Immunotherapies | Response is 60% or More If therapy is Given First Line at Annual Meeting 2018
Up Next Autoplay
Annual meeting of the Society for Immunotherapy of Cancer (SITC) 2019 Polynoma Presenting Interim Phase III Evidence for Its Investigational Melanoma Vaccine, Seviprotimut-L
Annual meeting of the Society for Immunotherapy of Cancer (SITC) 2019 Polynoma Presenting Interim Phase III Evidence for Its Investigational Melanoma Vaccine, Seviprotimut-L
Category: Melanoma and Skin Cancer
20 Views
Cancer-News 1 week
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Category: Melanoma and Skin Cancer
23 Views
Cancer-News 1 month
Will the CheckMate 204 data affect clinicians?
Will the CheckMate 204 data affect clinicians?
Category: Melanoma and Skin Cancer
11 Views
moasc 2 months
CheckMate 204 Study
CheckMate 204 Study
Category: Melanoma and Skin Cancer
10 Views
moasc 2 months
Clinicians could change the way they manage their patients
Clinicians could change the way they manage their patients
Category: Melanoma and Skin Cancer
3 Views
moasc 2 months
Fixing toxic therapy
Fixing toxic therapy
Category: Melanoma and Skin Cancer
6 Views
moasc 2 months
Alternate dosing for immunotherapy
Alternate dosing for immunotherapy
Category: Melanoma and Skin Cancer
2 Views
moasc 2 months
Is this data practice changing for clinicians?
Is this data practice changing for clinicians?
Category: Melanoma and Skin Cancer
1 Views
moasc 2 months
IMNC Data
IMNC Data
Category: Melanoma and Skin Cancer
4 Views
moasc 2 months
Follow up on The Long-Term Checkmake-004 in Metastatic Melanoma
Follow up on The Long-Term Checkmake-004 in Metastatic Melanoma
Category: Melanoma and Skin Cancer
20 Views
obr 4 months